Abstract
Purpose
Methods
Findings
Implications
Key words
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical TherapeuticsReferences
- Diffuse large B-cell non-Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2012; 23: vii78-vii82
Integraal kankercentrum Nederland. http://www.cijfersoverkanker.nl/selecties/dataset_1/img54137bd66fe02. Last accessed in November 2014
Cancer Research United Kingdom. Statistics and outlook for non-Hodgkin lymphoma. http://www.cancerresearchuk.org/about-cancer/type/non-hodgkins-lymphoma/treatment/statistics-and-outlook-for-non-hodgkins-lymphoma. Last accessed in November 2014
Hemato-Oncology Foundation for Adults Netherlands (HOVON). Diffuse large B-cell lymphoma (DLBCL). http://hovon.nl/behandeladvies/behandeladvies-lymfomen/dlbcl.html. Last accessed in November 2014
- CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.N Engl J Med. 2002; 346: 235-242
- CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera international trial (MInT) group.Lancet Oncol. 2011; 12: 1013-1022
- Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in british columbia.J Clin Oncol. 2005; 23: 5027-5033
European Medicines Agency. Summary of product specifications for MabThera (both IV and SC). www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf. Last accessed in November 2014
- Evaluation of the safety and feasibility of rapid rituximab infusion.Asia Pac J Clin Oncol. 2012; 8: 71-75
- Safety of rapid rituximab infusion in adult cancer patients: a systematic review.Int J Nurs Pract. 2011; 17: 357-369
Hoffmann-La Roche. Roche’s new time-saving subcutaneous formulation of MabThera approved in Europe for the treatment of common forms of non-Hodgkin Lymphoma; press release. http://www.roche.com/media/media_releases/med-cor-2014-03-28.htm. Last accessed in November 2014
- Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study.Lancet Oncol. 2014; 15: 343-352
Hoffmann-La Roche. A study of SubcutaneousVersus intravenous MabThera/rituxan (rituximab) in combination with CHOP chemotherapy in patients with previously untreated CD20-positive diffuse large B-cell lymphoma. http://www.clinicaltrials.gov/ct2/show/NCT01649856?term=IIIB+study+to+investigate+the+efficacy+of+subcutaneous+%28SC%29+rituximab+versus&rank=1. Last accessed in November 2014
- Recombinant human hyaluronidase (rHuPH20): An enabling platform for subcutaneous drug and fluid administration.Expert Opin Drug Deliv. 2007; 4: 427-440
F. Hoffmann-La Roche. A comparative, randomized, parallel-group, multi-centre, phase IIIb study to investigate the efficacy of subcutaneous (sc) rituximab versus intravenous (iv) rituximab both in combination with CHOP. https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-000669-19. Last accessed in November 2014
Hakkaart- van Roijen L, Tan SS, Bouwmans C.A.M. (2012). Handleiding voor kostenonderzoek. http://www.zorginstituutnederland.nl/binaries/content/documents/zinl-www/documenten/publicaties/overige-publicaties/1007-handleiding-voor-kostenonderzoek/Handleiding+voor+kostenonderzoek.pdf. Last accessed in November 2014
Nederlandse Vereniging van Ziekenhuizen (2011). Cao ziekenhuizen 2011 - 2014. http://www.nvz-ziekenhuizen.nl/cao-kenniscentrum/cao/cao-ziekenhuizen-2011-2014. Last accessed in November 2014
- The unit costs of inpatient hospital days, outpatient visits, and daycare treatments in the fields of oncology and hematology.Value Health. 2010; 13: 712-719
Trading Economies. Netherlands inflation rate 1971-2015 (in accordance with Statistics Netherlands). http://www.tradingeconomics.com/netherlands/inflation-cpi. Last accessed in June 2015
- RITUXAN® (Rituximab) full prescribing information for US market.Genentech, Inc., 2013
- Patient Preference for Subcutaneous or Intravenous Administration of Rituximab in Previously Untreated CD20+ Non-Hodgkin Lymphoma: Interim Data from the PrefMab Study.P467, European Hematology Association (EHA) 19th Annual Congress,12-15 June 2014, Milan, Italy2014
- Subcutaneous versus intravenous rituximab in patients with non-hodgkin lymphoma a time and motion study in the United Kingdom.Journal of Medical Economics. 2014; 17: 459-468
- Subcutaneous trastuzumab (herceptin®): A UK time and motion study in comparison with intravenous formulation for the treatment of patients with HER2-positive early breast cancer.Recent Rec Cancer. 2013; 2: 133-140
Shpilberg O., Jackisch C. Subcutaneous administration of rituximab (MabThera) and trastuzumab (herceptin) using hyaluronidase. Br J Cancer. 109:1556–1561.
- Ready-to-use injection preparations versus conventional reconstituted admixtures.Pharmacoeconomics. 2002; 20: 529-536
